Detection of Anaplasma capra in Patients with Suspected Crimean-Congo Hemorrhagic Fever, Turkey, 2022.

IF 7.9 2区医学 Q1 IMMUNOLOGY

Emerging Infectious Diseases Pub Date : 2026-10-01 DOI:10.3201/eid3210.251049

Kursat Altay, Nazif Elaldi, Ufuk Erol, Binnur Koksal, Omer Faruk Sahin, Ayse Nur Pektas, Seyit Ali Buyuktuna, Murtaza Oz, Yasemin Cakır Kıymaz, Tuba Nur Tasseten, Husnu Furkan Sakar, Mehmet Bakir

{"title":"Detection of Anaplasma capra in Patients with Suspected Crimean-Congo Hemorrhagic Fever, Turkey, 2022.","authors":"Kursat Altay, Nazif Elaldi, Ufuk Erol, Binnur Koksal, Omer Faruk Sahin, Ayse Nur Pektas, Seyit Ali Buyuktuna, Murtaza Oz, Yasemin Cakır Kıymaz, Tuba Nur Tasseten, Husnu Furkan Sakar, Mehmet Bakir","doi":"10.3201/eid3210.251049","DOIUrl":null,"url":null,"abstract":"<p><p>Anaplasma capra is a recently discovered bacterial tickborne pathogen that was first identified in goats in 2012 and later in humans in China in 2015. We detected and genetically characterized A. capra in adult patients with suspected Crimean-Congo hemorrhagic fever (CCHF) in Turkey during the 2022 outbreak. We screened all patients for A. capra by using nested PCR targeting the gltA and groEL genes. We confirmed CCHF by molecular and serological tests. Of 263 patients, 6 (2.28%) were positive for A. capra. Sequence analysis revealed 84.16%-100% gltA gene similarity and 90.24%-100% groEL gene similarity with GenBank entries. Phylogenetic analysis confirmed all A. capra gene sequences belonged to genotype 1. Our results demonstrate clinical evidence of genotype 1 A. capra infection in humans. Our findings highlight the need for clinicians to consider A. capra in the differential diagnosis of CCHF-like symptoms, especially in endemic areas.</p>","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":"32 10","pages":"1561-1570"},"PeriodicalIF":7.9000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632829/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3210.251049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Anaplasma capra is a recently discovered bacterial tickborne pathogen that was first identified in goats in 2012 and later in humans in China in 2015. We detected and genetically characterized A. capra in adult patients with suspected Crimean-Congo hemorrhagic fever (CCHF) in Turkey during the 2022 outbreak. We screened all patients for A. capra by using nested PCR targeting the gltA and groEL genes. We confirmed CCHF by molecular and serological tests. Of 263 patients, 6 (2.28%) were positive for A. capra. Sequence analysis revealed 84.16%-100% gltA gene similarity and 90.24%-100% groEL gene similarity with GenBank entries. Phylogenetic analysis confirmed all A. capra gene sequences belonged to genotype 1. Our results demonstrate clinical evidence of genotype 1 A. capra infection in humans. Our findings highlight the need for clinicians to consider A. capra in the differential diagnosis of CCHF-like symptoms, especially in endemic areas.

查看原文本刊更多论文

疑似克里米亚-刚果出血热患者卡普拉无原体的检测，土耳其，2022。

capra无原体是最近发现的一种细菌性蜱传病原体，最早于2012年在山羊身上发现，后来于2015年在中国的人类身上发现。在2022年爆发期间，我们在土耳其疑似克里米亚-刚果出血热（CCHF）的成年患者中检测到了卡普拉单胞杆菌并对其进行了遗传鉴定。我们采用针对gltA和groEL基因的巢式PCR筛选所有患者。我们通过分子和血清学检测确认了CCHF。263例患者中，6例（2.28%）阳性。序列分析显示gltA基因与GenBank条目的相似性为84.16% ~ 100%，groEL基因与GenBank条目的相似性为90.24% ~ 100%。系统发育分析证实所有基因序列均为基因1型。我们的结果提供了基因1型卡普拉在人类感染的临床证据。我们的研究结果强调了临床医生在鉴别诊断cchf样症状时，特别是在流行地区，需要考虑卡普拉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging Infectious Diseases 医学-传染病学

CiteScore

17.30

自引率

1.70%

发文量

505

审稿时长

1 months

期刊介绍： Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination. Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.